Vaccination against COVID-19 in various circumstances from 1.5.2023



Age group	Recommended vaccine for primary vaccination	Number of doses primary vaccination	Interval from primary vaccination to first booster	Recommended vaccine for booster	Recommended vaccine for additional booster doses*	Timing of booster doses for risk groups*	Timing of vaccination according to this scheme following COVID-19 infection
60 years and older	Pfizer bivalent /Moderna bivalent	2	4 months	Pfizer/Moderna, latest/broadest- spectrum version at any time	Pfizer/Moderna, latest/broadest-spectrum version at any time	Yearly in the autumn or on medical advice up to twice a year	No less than 4 weeks after start of illness
40–59 years	Pfizer bivalent /Moderna bivalent [¥]	2	4 months [¥]	Pfizer/Moderna, latest/broadest- spectrum version at any time [¥]	Pfizer/Moderna, latest/broadest-spectrum version available at any time – only for risk and priority groups**	Yearly in the autumn or on medical advice up to twice a year	No less than 4 weeks after start of illness
18–39 years	Pfizer bivalent [¥]	2	4 months [¥]	Pfizer/Moderna, latest/broadest- spectrum version at any time [¥]	Pfizer/Moderna, latest/broadest-spectrum version available at any time – only for risk and priority groups**	Yearly in the autumn or on medical advice up to twice a year	No less than 4 weeks after start of illness
12–17 years	Pfizer bivalent [¥]	2	4 months [¥]	Pfizer, latest/broadest- spectrum version at any time [¥]	Pfizer, latest/broadest-spectrum version at any time – only for risk groups	Yearly in the autumn or on medical advice up to twice a year	No less than 4 weeks after start of illness
5–11 years	Pfizer bivalent 10 mcg/dose [¥]	2	4 months¥	Pfizer 10 mcg/dose, latest/broadest- spectrum version at any time [¥]	Pfizer 10 mcg/dose, latest/broadest-spectrum version at any time – only for risk groups	Yearly in the autumn or on medical advice up to twice a year	No less than 4 weeks after start of illness
0–4 years	None [vaccine not available in Iceland]						

^{*} Additional booster doses only recommended for persons at increased personal risk for severe illness (risk groups: all over age 60, younger with chronic medical conditions)

^{**} Priority groups (health care workers, family members of persons at risk etc.): At least one dose of bivalent vaccine recommended, even if had previously completed recommended dose number with monovalent vaccine

 $^{^{4}}$ Vaccination of risk groups within the age group most important but vaccine accessible to others.